secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001193125-22-281213
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno reports Q3 2022 net loss of $6.1M; initiates randomized withdrawal of DCCR study for PWS
--------------------------------------------------------------------------------

- Cash at Sep 30, 2022: $19.8M; sufficient to fund operations through H1 2023 top-line data.
- Net loss Q3 2022: $6.1M ($0.76 per share) vs $8.1M ($1.53) YoY.
- R&D expense decreased to $3.8M from $5.0M YoY; G&A down to $2.3M.
- Initiated randomized withdrawal period of Study C602 for DCCR in PWS; top-line data expected H1 2023.
- FDA acknowledged that data from the study could support NDA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312522281213/0001193125-22-281213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312522281213/d417158d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-281213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer